This is driving the usage of home sleep screening devices for sleep disorder cases, and subsequently increasing the revenue generation of the home sleep screening devices market.
There are a range of technologically enhanced sleep tech devices on the market, including wearable smart watches and bands, rings, sleep pads, headbands, beds and ear plugs.
, is pleased to announce the launch of its first new signal since the original six were made available to the public.
The upcoming launch of the “Bedtime” signal marks a significant milestone for Hapbee’s platform, as it demonstrates the Company’s ability to execute on its business model of seamless, new signal releases intended to enhance user experience and optionality.
“Launching a new signal demonstrates Hapbee’s ability to deploy new technology across both app and firmware updates.
According to a recent study highlighted by StudyFinds.org, “Nearly two-thirds of Americans struggle to fall asleep each night.” Hapbee intends to service this growing marketplace through the launch of its new signal and other initiatives.
‘Bedtime’ aims to help people unplug from all the noise in their day and to get the good night’s sleep they deserve,” says Scott Donnell, CEO of Hapbee.
Prior to the development of the Company’s new “Bedtime” signal, Hapbee’s wearable came pre-loaded with six signals: Alert, Happy, Calm, Relax, Focus and Deep Sleep .
And to examine another angle regarding sleep issues, Forbes recently published an article that according to a new study, disrupted sleep, insomnia and daily burnout are all linked to a higher risk of coronavirus infection, more severe Covid-19 symptoms and longer recovery periods in high-risk healthcare workers.
“This study spotlights an often-neglected area of wellbeing: the need for quality sleep and re-charge time to prevent burnout and its consequences,” Minha Rajput-Ray, Medical Director of NNEdPro Global Centre for Nutrition & Health, said in a statement.
, a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, recently announced that its co-development partner, Bharat Biotech, shared positive results of the second interim analysis of its Phase 3 study of COVAXIN, a whole virion inactivated COVID-19 vaccine candidate.
We believe that COVAXIN can help change the course of this pandemic by preventing severe COVID-19 disease including hospitalizations by 100% as well as significantly limit the spread of asymptomatic COVID-19 infections based on efficacy shown to date.
The Saphyr-based method was capable of determining the timing, speed and origin of DNA replication in human cells at a coverage level that is thousands of times higher than what earlier methods such as nanopore sequencing allowed.
The body of humans and other organisms develop and grow when cells divide, and for each division the entire genome needs to be replicated.
. The patient was dosed at the EB House Austria, a center of expertise for epidermolysis bullosa at the University Hospital Salzburg, Austria.
“We are excited to expand our pipeline and we look forward to developing TNX-3500 as a potential treatment for COVID-19 and emerging variants,” said Seth Lederman, M.D., Tonix’s President and Chief Executive Officer.
FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.
You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.